Suppression of bladder cancer growth by adeno-associated virus vector-mediated combination of HSV-TK and endostatin in vitro

Clinical Laboratory

Volumn 59, Issue 9-10, 2013, Pages 1077-1089

  Pan, Jian Gang ^a   Luo, Run Qi ^a   Zhou, Xing ^a   Han, Rui Fa ^b   Zeng, Ge Wa ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Adeno associated viruses; Bladder cancer; Endostatin; Gene therapy; HSV

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; DNA FRAGMENT; ENDOSTATIN; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; SITIMAGENE CERADENOVEC;

ADENO ASSOCIATED VIRUS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CELL DEATH; GENE AMPLIFICATION; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; IN VITRO STUDY; INVERTED TERMINAL REPEAT; NUDE MOUSE; SIGNAL TRANSDUCTION; VIRUS PARTICLE; XENOGRAFT;

ANIMALS; CELL LINE; DEPENDOVIRUS; ENDOSTATINS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, NUDE; SIMPLEXVIRUS; THYMIDINE KINASE; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886423632     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.121021     Document Type: Article

References (30)

1. Voutsinas GE, Stravopodis DJ. Molecular targeting and gene delivery in bladder cancer therapy. J BUON 2009 Sep; 14 Suppl 1:S69-78.
2. Malkowicz SB. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol 2000;18:280-8.
3. Edelman MJ. New approaches to treatment of metastatic bladder cancer. Curr Oncol Rep 2000;2:379-85.
4. Block T. Chemotherapy of bladder carcinoma. Current status and trends. Urologe A 1994;33:557-67. (Pubitemid 24360556)
5. Witjes JA, Wullink M, Oosterhof GO, de Mulder P. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol 1997;31:414-9. (Pubitemid 27234629)
6. Freund CTF, Tong XW, Rowley D, et al. Combination of adeno-virus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urologic Oncology: Seminars and Original Investigations 2003;21:197-205. (Pubitemid 36723707)
7. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006;4:218-27. (Pubitemid 44496015)
8. Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther 2005;4:512-7. (Pubitemid 41351222)
9. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 2007;28:87-114.
10. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwilliger EF. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 2008;58:5673-7.
11. Sharma A, Tandon M, Bangari DS, Mittal SK. Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther 2009;4:117-38.
12. Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 2003;3:13-26.
13. Kagawa S, He C, Gu J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001;61:3330-8. (Pubitemid 32695022)
14. Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther. 2000;11:1569-76. (Pubitemid 30670608)
15. Ma H, Liu Y, Liu S, et al. Recombinant adeno-associated virusmediated TRAIL gene therapy suppresses liver metastatic tumors. International Journal of Cancer 2005;116:314-21. (Pubitemid 40967271)
16. Streck CJ, Dickson PV, Ng CY, et al. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clinical Cancer Research 2005;11:6020-9. (Pubitemid 41170334)
17. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991;10:3941-50. (Pubitemid 21905423)
18. El-Aneed A. An overview of current delivery systems in cancer gene therapy. Journal of Controlled Release 2004;94:1-14. (Pubitemid 37542373)
19. Pan JG, Zhou X, Zeng GW, Han RF. Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumor Biology 2011;32(2):301-10.
20. Pan JG, Zhou X, Luo RQ, Han RF. The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma. Med Oncol 2012;29(3):1938-47.
21. AAV Helper-Free System Instruction Manual. Revision A.02. www.stratagene.com.
22. Wu XB, Dong XY, Wu ZJ, et al. A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chinese Science Bulletin 2001;6:485-90.
23. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector tool kit for human gene therapy. Mol Ther 2006;14:316-27. (Pubitemid 44184972)
24. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associate virus vector. J Virol 2009;70:8098-108.
25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1(1995)27-31.
26. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene therapy of cancer: Current status and future prospects. Molecular Aspects of Medicine 2007;28:87-114.
27. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of Endostatin enhances the treatment efficacy of radiation. Radiotherapy and Oncology 2003;66:1-9. (Pubitemid 36135998)
28. Yu YF, Chen ZW, Li ZM, Li ZH, Lu S. The Effects of Cetuximab alone and in Combination with Endostatin on Vascular Endothelial Growth Factor and Interleukin-8 Expression in Human Lung Adenocarcinoma Cells. Current Therapy Res 2009;70:116-28.
29. Kyoko H, Lee J, Yoshie M, Naoki T, Hideo N, Toshimitsu H. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J Gen Med 2006;8:1056-67. (Pubitemid 44283002)
30. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gapjunctional intercellular communication. Cancer Res 2000;60:-3989-99.